부비강암 시장 : 시장 규모, 점유율, 성장 분석 - 진단법별, 암 스테이지별, 치료법별, 최종 사용자별, 지역별 산업 예측(2025-2032년)
Paranasal Sinus Cancer Market Size, Share, and Growth Analysis, By Diagnosis (Medical history and physical examination, Imaging tests), By Stage of Cancer (Advanced, Localized), By Treatment, By End User, By Region - Industry Forecast 2025-2032
세계의 부비강암 시장 규모는 2023년에 19억 달러로 평가되었고, 2024년 20억 2,000만 달러에서 2032년에는 33억 2,000만 달러로 성장할 전망이며, 예측 기간인 2025-2032년 CAGR 6.4%로 성장할 것으로 예측됩니다.
세계의 부비강암 시장은 두경부암 환자 증가, 진단 및 생검 기술의 진보, 치료 옵션의 강화, 의료 부문의 의식 향상 등을 배경으로 큰 성장을 이루고 있습니다. 정부와 의료기관은 시장 확대를 지원하기 위해 인지도 향상, 연구 개발에 대한 자금 제공, 효과적인 공공 정책 제정, 엄격한 규제 실시 등을 적극적으로 추진하고 있습니다. 업계, 특히 인공지능의 혁신은 진단학에 변화를 가져오고, AI는 암의 조기 발견을 위한 MRI와 CT 스캔의 정밀도를 향상시키고 있습니다. 머신러닝 알고리즘은 치료를 개별화하기 위한 임상 데이터 분석에 사용됩니다. 또한 AI와 블록체인을 통합한 원격 의료 플랫폼의 이용이 확대됨에 따라 원격 진단이 용이해지고 진단 오류가 줄어 환자에 맞는 치료에 기여하고 있습니다.
목차
서문
분석 기법
- 정보 조달
- 2차 및 1차 데이터의 수법
- 시장 규모 예측
- 시장의 상정 및 제약
주요 요약
- 시장 개요 및 전망
- 수급 동향의 분석
- 부문별 기회 분석
시장 역학 및 전망
- 시장 개요
- 시장 규모
- 시장 역학
- 성장 촉진요인 및 기회
- 성장 억제요인 및 과제
- Porter's Five Forces 분석
주요 시장 인사이트
- 주요 성공 요인
- 경쟁도
- 주요 투자 기회
- 시장 생태계
- 시장 매력도 지수(2024년)
- PESTEL 분석
- 거시경제지표
- 밸류체인 분석
- 가격 분석
세계의 부비강암 시장 규모 및 CAGR : 진단법별(2025-2032년)
- 시장 개요
- 병력 및 신체검사
- 화상 검사
- X선
- CT(컴퓨터 단층 촬영) 스캔
- MRI(자기 공명 화상) 스캔
- PET(양전자 방출 단층 촬영) 스캔
- 생검
- 세침 흡인 생검(FNA)
- 절개 생검 및 절제 생검
- 기타
세계의 부비강암 시장 규모 및 CAGR : 암 스테이지별(2025-2032년)
세계의 부비강암 시장 규모 및 CAGR : 치료법별(2025-2032년)
세계의 부비강암 시장 규모 및 CAGR : 최종 사용자별(2025-2032년)
- 시장 개요
- 병원 및 클리닉
- 암치료 및 연구센터
- 연구실
- 기타
세계의 부비강암 시장 규모 및 CAGR(2025-2032년)
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- GCC 국가
- 남아프리카
- 기타 중동 및 아프리카
경쟁 구도
- 상위 5개사 비교
- 주요 기업의 시장 포지셔닝(2024년)
- 주요 기업이 채용한 전략
- 시장의 최근 동향
- 주요 기업의 시장 점유율(2024년)
- 주요 기업 프로파일
- 기업 개요
- 제품 포트폴리오 분석
- 부문별 점유율 분석
- 수익의 전년대비 비교(2022-2024년)
주요 기업 프로파일
- F. Hoffmann-La Roche AG(Switzerland)
- Bristol Myers Squibb(United States)
- Merck & Co., Inc.(United States)
- Pfizer Inc.(United States)
- Eli Lilly and Company(United States)
- AstraZeneca plc(United Kingdom)
- Novartis AG(Switzerland)
- Sanofi SA(France)
- Johnson & Johnson(United States)
- Bayer AG(Germany)
- Exelixis, Inc.(United States)
- Ipsen Biopharmaceuticals Inc.(France)
- GlaxoSmithKline plc(GSK)(United Kingdom)
- AbbVie Inc.(USA)
- Kura Oncology, Inc.(USA)
- Nanobiotix SA(France)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Takeda Pharmaceutical Company Limited(Japan)
- Mayo Clinic(United States)
- MD Anderson Cancer Center(United States)
결론 및 권고
AJY
Global Paranasal Sinus Cancer Market size was valued at USD 1.9 billion in 2023 and is poised to grow from USD 2.02 billion in 2024 to USD 3.32 billion by 2032, growing at a CAGR of 6.4% during the forecast period (2025-2032).
The global paranasal sinus cancer market is experiencing significant growth, driven by a rise in head and neck cancer cases, advancements in diagnostic and biopsy technologies, enhanced treatment options, and increased health sector awareness. Government and health organizations are actively promoting awareness, funding R&D, enacting effective public policies, and implementing strict regulations to support market expansion. Innovations in the industry, particularly in artificial intelligence, are transforming diagnostics, with AI improving MRI and CT scan accuracy for early cancer detection. Machine learning algorithms are being employed to analyze clinical data to personalize treatments. Additionally, the growing use of telemedicine platforms, incorporating AI and blockchain, facilitates remote consultations, reducing diagnostic errors and contributing to tailored patient care.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Paranasal Sinus Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Paranasal Sinus Cancer Market Segments Analysis
Global Paranasal Sinus Cancer Market is segmented by Diagnosis, Stage of Cancer, Treatment, End User and region. Based on Diagnosis, the market is segmented into Medical history and physical examination, Imaging tests, Biopsy and Others. Based on Stage of Cancer, the market is segmented into Advanced, Localized and Recurrent. Based on Treatment, the market is segmented into Surgery, Radiotherapy and Chemotherapy. Based on End User, the market is segmented into Hospital & Clinics, Cancer Treatment & Research Center, Research Laboratories and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Paranasal Sinus Cancer Market
The global paranasal sinus cancer market is witnessing significant transformation, largely driven by the increasing prevalence of tobacco consumption, which irritates and inflames the nasal cavity and heightens the risk of developing paranasal sinus cancer. This surge in cases necessitates sophisticated treatment options and diagnostic methods, including nasal endoscopy, CT scans, and MRI scans. As a result, there is a growing demand for products and services related to the diagnosis and treatment of paranasal sinus cancer. Consequently, the market is expanding rapidly, reflecting the urgent need for advanced healthcare solutions to address this serious condition.
Restraints in the Global Paranasal Sinus Cancer Market
The global market for paranasal sinus cancer faces significant restraints primarily due to its rarity and lack of public awareness. This limited recognition contributes to delays in diagnosis and insufficient medical support for patients. Furthermore, the infrequent nature of the disease diminishes the willingness of both governmental bodies and pharmaceutical companies to invest in research and development for effective treatments. Consequently, this translates into a slower progression in therapeutic advancements and awareness campaigns, ultimately hindering the growth of the paranasal sinus cancer market and leaving patients with fewer options for care and support.
Market Trends of the Global Paranasal Sinus Cancer Market
The Global Paranasal Sinus Cancer market is witnessing significant growth fueled by advancements in technology. Innovations such as liquid biopsies and next-generation sequencing are enhancing the detection and monitoring of early symptoms, allowing for timely intervention. Furthermore, the integration of artificial intelligence into diagnostic imaging, such as MRI and CT scans, is revolutionizing treatment protocols by providing personalized analyses of patient medical histories and responses to therapies. These technological advancements not only facilitate accurate diagnosis but also improve treatment outcomes, driving the demand for sophisticated healthcare solutions within the paranasal sinus cancer market. As technology evolves, continued growth is anticipated in this sector.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
Global Paranasal Sinus Cancer Market Size by Diagnosis & CAGR (2025-2032)
- Market Overview
- Medical history and physical examination
- Imaging tests
- X-rays
- CT (computed tomography) scan
- MRI (magnetic resonance imaging) scan
- PET (positron emission tomography) scan
- Biopsy
- Fine needle aspiration (FNA) biopsy
- Incisional and excisional biopsies
- Others
Global Paranasal Sinus Cancer Market Size by Stage of Cancer & CAGR (2025-2032)
- Market Overview
- Advanced
- Localized
- Recurrent
Global Paranasal Sinus Cancer Market Size by Treatment & CAGR (2025-2032)
- Market Overview
- Surgery
- Radiotherapy
- Chemotherapy
Global Paranasal Sinus Cancer Market Size by End User & CAGR (2025-2032)
- Market Overview
- Hospital & Clinics
- Cancer Treatment & Research Center
- Research Laboratories
- Others
Global Paranasal Sinus Cancer Market Size & CAGR (2025-2032)
- North America (Diagnosis, Stage of Cancer, Treatment, End User)
- Europe (Diagnosis, Stage of Cancer, Treatment, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Diagnosis, Stage of Cancer, Treatment, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Diagnosis, Stage of Cancer, Treatment, End User)
- Brazil
- Rest of Latin America
- Middle East & Africa (Diagnosis, Stage of Cancer, Treatment, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Exelixis, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ipsen Biopharmaceuticals Inc. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc (GSK) (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kura Oncology, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Nanobiotix S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mayo Clinic (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- M.D. Anderson Cancer Center (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
